Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
Recommended CitationMcBride, Amanda; Houtmann, Sarah; Wilde, Lindsay; Vigil, Carlos; Eischen, Christine M.; Kasner, Margaret; and Palmisiano, Neil, "The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome." (2019). Department of Medical Oncology Faculty Papers. Paper 93.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.